USFDA completes inspection of Lupin’s Nagpur facility
8th Aug 2019

United States Food and Drug Administration (USFDA) has completed inspection carried out at Lupin’s Nagpur oral solid manufacturing facility. The inspection was carried out between August 5, 2019 and August 8, 2019. The inspection for the oral solid facility at Nagpur closed without any 483 observations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.